MARKET

AYLA

AYLA

Ayala Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.98
-0.29
-2.19%
Closed 16:00 10/28 EDT
OPEN
12.71
PREV CLOSE
13.27
HIGH
13.25
LOW
12.71
VOLUME
5.41K
TURNOVER
--
52 WEEK HIGH
16.50
52 WEEK LOW
8.62
MARKET CAP
165.88M
P/E (TTM)
-7.3897
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Ayala Pharmaceuticals (AYLA) - Updated ACCURACY Phase 2 Data Review Presentation
The following slide deck was published by Ayala Pharmaceuticals, Inc. in conjunction with this event.
Seekingalpha · 09/23 10:47
Ayala Pharmaceuticals Inc (AYLA) Investor Presentation - Slideshow
The following slide deck was published by Ayala Pharmaceuticals, Inc. in conjunction with this event.
Seekingalpha · 09/22 10:59
Cassava Sciences, Evogene leads the healthcare gainers' pack, Ayala Pharmaceuticals, Clovis Oncology amond major losers
Gainers: Cassava Sciences (SAVA) +41%, Evogene (EVGN) +26%, AlloVir (ALVR) +15%, Abeona Therapeutics (ABEO) +15%, Sonoma Pharmaceuticals (SNOA) +14%.Losers: Ayala Pharmaceuticals (AYLA) -12%, Clovis Oncology (CLVS) -10%, Checkpoint Therapeutics (CKPT) -9%, Seres Therapeutics (MCRB) -8%, Innate Pharma (IPHA) -5%.
Seekingalpha · 09/18 14:56
Ayala Pharma under pressure on underwhelming AL101 data in type of cancer affecting the glandular tissues
Ayala Pharmaceuticals ([[AYLA]] -10.2%) has announced interim data from the ongoing Phase 2 ACCURACY trial of AL101 for the treatment of recurrent/metastatic (R/M) adenoid cystic carcinoma ((ACC)) harboring Notch-activating mutations. Data
Seekingalpha · 09/18 14:49
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 09/18 11:30
Ayala Pharma To Present Interim Data From Phase 2 ACCURACY Trial Of AL1010 For Treatment OF Recurrent/Metastatic Adenoid Cystic Carcinoma With Notch Activating Mutations At European Society for Medical Oncology Congress Sept. 18
Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala or the Company), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive
Benzinga · 09/18 11:02
Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma with Notch Activating Mutations at ESMO 2020
– Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control rate- Company to host virtual KOL event to review data today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq
GlobeNewswire · 09/18 11:00
SRNE, CRDF, INO and PLAY among midday movers
Gainers: Ebang International (EBON) +42%.Cardiff Oncology (CRDF) +34%.Herman Miller (MLHR) +32%.Aemetis (AMTX) +22%.Entera Bio (ENTX) +21%.NextDecade (NEXT) +19%.ReneSola (SOL) +16%.51job (JOBS) +16%.Sorrento Therapeutics (SRNE) +14%Ayala Pharmaceuticals (AYLA) +13%.Losers: The Marcus (MCS) -33%.Dave & Buster's Entertainment
Seekingalpha · 09/17 16:43
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AYLA. Analyze the recent business situations of Ayala Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AYLA stock price target is 21.13 with a high estimate of 25.00 and a low estimate of 12.50.
EPS
Institutional Holdings
Institutions: 8
Institutional Holdings: 2.59M
% Owned: 20.25%
Shares Outstanding: 12.78M
TypeInstitutionsShares
Increased
0
0
New
8
2.59M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AYLA
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company. It is focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company’s portfolio of product candidates include AL101 and AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. The Company’s lead product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor (GSI). It is evaluating AL101 as a monotherapy in an open-label Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma (R/M ACC) for patients bearing Notch-activating mutations. The Company refer this trial as the ACCURACY trial. The Company uses advanced sequencing to identify patients with Notch-activating mutations, an approach that will enable it to target the patient population with cancers.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Ayala Pharmaceuticals Inc stock information, including NASDAQ:AYLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AYLA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AYLA stock methods without spending real money on the virtual paper trading platform.